JW CAYMAN THERAPEUTICS CO LTD. revenue breakdown overview

JW CAYMAN THERAPEUTICS CO LTD. revenue for the last year amounted to 21.67 M USD, the most of which — 22.07 M USD — came from its highest performing source at the moment, Autologous Chimeric Antigen Receptor T-cell Immunotherapy, the year earlier bringing 24.60 M USD. The greatest contribution to the revenue figure was made by China — last year it brought JW CAYMAN THERAPEUTICS CO LTD. 22.07 M USD, and the year before that — 24.60 M USD.